Proteocyte AI

Proteocyte AI A Canadian molecular diagnostics company with a novel technology that determines the risk of a head

Better cancer diagnostics

Our novel diagnostic technology, Straticyte™, determines the risk of a head and neck lesion becoming cancerous in the near future. If the risk is high, clinicians can provide early interventions. Clinicians can follow-up effectively with moderate and low risk lesions. Accurate early diagnosis and treatment will drastically improve the clinical outcomes and quality of life for people with head and neck cancer.

Proteocyte AI is proud to be a Platinum Sponsor of the 2026 AAOM Annual Conference, taking place mid-April.📍 Hyatt Regen...
03/24/2026

Proteocyte AI is proud to be a Platinum Sponsor of the 2026 AAOM Annual Conference, taking place mid-April.

📍 Hyatt Regency DFW, 2334 N. International Pkwy, DFW Airport, TX 75261, USA
🗓️ April 22, 2026 - April 25, 2026

Accepted poster:
Identifying Malignant Transformation Risk of Dysplastic Oral Lesions with Straticyte®

We look forward to connecting with the oral medicine community and sharing how Straticyte® is advancing personalized oral cancer risk assessment.

Learn more about the conference: https://site.pheedloop.com/event/2026AAOM/home


Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

You order the test. We do the rest.STRATICYTE® is designed to integrate seamlessly into clinical workflows—providing obj...
03/17/2026

You order the test. We do the rest.

STRATICYTE® is designed to integrate seamlessly into clinical workflows—providing objective, AI-powered risk stratification without adding complexity or burden.

By combining validated proteomic biomarker analysis with advanced digital pathology, STRATICYTE® goes beyond traditional histopathology to deliver a personalized 5-year oral cancer risk assessment.

Your STRATICYTE® report delivers clear, actionable insight—helping identify patients who may benefit from closer surveillance or earlier intervention, while avoiding overtreatment for those at lower risk.

Smarter risk assessment. Clearer decisions. Better patient management.

Learn how STRATICYTE® fits into your practice:
👉 https://proteocyte.com/straticyte/


Seattle Jaw Surgery Society of OMS Administrators SPOHNC Mouth Cancer Foundation Osteology Foundation Oral Health Foundation SurgeOn Events

Oral cancer outcomes haven’t improved enough—and early insight matters.Ask your healthcare provider about Straticyte®.Th...
03/12/2026

Oral cancer outcomes haven’t improved enough—and early insight matters.

Ask your healthcare provider about Straticyte®.
This clinically accredited test helps assess a patient’s personalized 5-year risk of oral cancer, supporting earlier, more informed care decisions.

Knowledge empowers conversations. Conversations can change outcomes.

Learn more at www.proteocyte.com


American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

“Straticyte is an innovative new test that can help us to better risk stratify patients and personalize their treatment....
03/10/2026

“Straticyte is an innovative new test that can help us to better risk stratify patients and personalize their treatment.”
— Dr. Deepak Kademani
Fellowship Director, Head and Neck Oncologic and Reconstructive Surgery
Minnesota Oral and Facial Surgery

STRATICYTE® can make a critical difference.
Using AI-driven biomarker analysis and digital pathology, STRATICYTE® supplements traditional histopathology by providing an objective, personalized 5-year oral cancer risk score.

Each STRATICYTE® report clearly classifies lesions as low risk or elevated risk, helping clinicians make more confident, evidence-based decisions around monitoring, intervention, and treatment planning.

Earlier insight enables smarter care—supporting timely intervention for high-risk patients while reducing unnecessary procedures for those at lower risk.

Learn more about STRATICYTE® and how it’s changing oral cancer risk assessment:
👉 https://proteocyte.com/straticyte/


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

Proteocyte AI would like to thank Dr. Jonathon Jundt (DDS, MD, FACS) and Allied OMS for the opportunity to speak with yo...
03/09/2026

Proteocyte AI would like to thank Dr. Jonathon Jundt (DDS, MD, FACS) and Allied OMS for the opportunity to speak with your membership about risk stratification in oral precancer—supporting our mission to bring early oral cancer prediction into everyday clinical practice.

Our team was proud to present “AI and Biomarker-Guided Diagnostics in Oral Lesions: Risk Stratification to Clinical Pathways,” alongside Dr. Anthony Morlandt and Dr. Paras B. Patel, whose passion and leadership continue to drive progress in oral disease diagnosis and surgical care.

Conversations like these are essential as the oral health community works toward earlier identification of high-risk lesions and more personalized patient management.

🎥 Watch the full presentation here:
https://vimeo.com/1166776243/70fe5d4b60

Learn more about STRATICYTE®, Proteocyte AI’s test designed to assess oral cancer risk:
https://proteocyte.com/straticyte/


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

Team Spotlight: Dr. Anthony Morlandt, MD, DDS, FACSWe’re proud to highlight Dr. Anthony Morlandt, Chief of Oral Oncology...
03/05/2026

Team Spotlight: Dr. Anthony Morlandt, MD, DDS, FACS

We’re proud to highlight Dr. Anthony Morlandt, Chief of Oral Oncology within the Department of Oral and Maxillofacial Surgery at the University of Alabama at Birmingham (UAB) Medicine. Dr. Morlandt is an academic head and neck surgeon with a focus on advancing oral cancer care. His oncology practice focuses on surgical treatment of tumors involving the oral cavity and oropharynx, salivary glands, skin of the head and neck, and skull base. His clinical and academic focus centers on helping clinicians and patients better understand individual risk associated with oral precancerous lesions.

His current research focuses on the use of prognostic biomarkers in the progression of oral dysplasia to cancer. His work has been published in more than 50 scientific articles and book chapters and he has given over 100 invited oral and video presentations. Dr. Morlandt received the Faculty Educator Development Award of the American Association of Oral and Maxillofacial Surgeons, the first in Alabama to do so. He has been inducted into the American Head and Neck Society and is a Fellow of both the American College of Surgeons and the American Association of Craniomaxillofacial Surgeons.
As Proteocyte AI's Chief Medical Officer, USA Dr. Morlandt’s expertise plays an important role in advancing the science behind STRATICYTE®, supporting more precise, patient-centered decision-making in oral cancer risk assessment.

“The Straticyte test represents an important step toward precision medicine in oral oncology, allowing clinicians to better risk-stratify dysplastic lesions and focus intervention on patients most likely to progress to cancer. By integrating objective molecular data with clinical judgment, we can move beyond qualitative histology alone and improve how we surveil and treat patients with potentially malignant oral disorders.”

đź”— Learn more: https://proteocyte.com/team/


Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

At Proteocyte AI, quality is embedded in everything we do.From training and technology development to clinical procedure...
02/24/2026

At Proteocyte AI, quality is embedded in everything we do.

From training and technology development to clinical procedures and services, our work is guided by a robust Quality Management System (QMS) and stringent regulatory standards.

Our commitment ensures reliable results, clinical confidence, and continued innovation—because our patients and partners deserve nothing less than our best.


American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health

Ordering STRATICYTE® is simple, secure, and fully supported by Proteocyte AI Client Services.👉 Complete Test Request For...
02/17/2026

Ordering STRATICYTE® is simple, secure, and fully supported by Proteocyte AI Client Services.

👉 Complete Test Request Form: https://proteocyte.com/ordering-options/
đź“„ Submit order: đź“§ Email: clientservices@proteocyte.com or đź“  Fax: 1-855-566-0488
📞 Questions? 📧 clientservices@proteocyte.com or 📱 1-833-577-6836

✔️ Secures payment from clinic or patient
✔️ Obtains unstained slides from the original OPMD biopsy lab
✔️ Facilitates specimen transfer to our lab*
✔️ Delivers the STRATICYTE® report in ~2–3 weeks from specimen receipt*

*Proprietary AI biomarker analysis and H&E and digitized image analysis performed at Proteocyte AI labs

US Lab Director: Dr. Paras Patel | CA Lab Director: Dr. Ken Pritzker


Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association

đź“„ New Research Supporting Predictive Biomarkers in OPMDsA peer-reviewed study highlights S100A7 as a promising predictiv...
02/10/2026

đź“„ New Research Supporting Predictive Biomarkers in OPMDs

A peer-reviewed study highlights S100A7 as a promising predictive biomarker for identifying oral potentially malignant disorders (OPMDs) at increased risk of transforming into oral squamous cell carcinoma (OSCC).

The study demonstrates that S100A7 expression—evaluated through immunohistochemistry and a signature risk algorithm—can differentiate transforming from non-transforming lesions with statistical significance.

This research reinforces the role of biomarker-driven, objective risk assessment in advancing oral cancer prediction and patient care.

đź”— Explore our publications: https://proteocyte.com/publications/


Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

Oral cancer can develop in any part of the mouth, including the lips, gums, tongue, and palate.This year alone, over 50,...
02/03/2026

Oral cancer can develop in any part of the mouth, including the lips, gums, tongue, and palate.

This year alone, over 50,000 North Americans will be diagnosed—and 1 in 5 cases will be fatal.

Despite advances in medicine, 5-year survival remains ~50%, and survival rates have seen little improvement over the past 30+ years.

Early detection and prediction are critical for improving outcomes.

That’s why STRATICYTE® helps predict oral cancer risk—supporting earlier, more informed patient management when it matters most.

To learn more about STRATICYTE®, visit www.proteocyte.com.


Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

Who is Proteocyte AI?Proteocyte AI is a privately owned med-tech company based on Hospital Row in downtown Toronto, with...
01/29/2026

Who is Proteocyte AI?

Proteocyte AI is a privately owned med-tech company based on Hospital Row in downtown Toronto, with labs in Canada and the US, dedicated to advancing how cancer risk is identified and managed. Our focus is developing cutting-edge diagnostic lab tests that use proteomic assays and AI-driven analysis to predict a patient’s future risk of developing cancer.

By identifying patients at high risk earlier, Proteocyte AI empowers clinicians to make more informed decisions and tailor patient management more effectively.

STRATICYTE® is our transformative test that has received clinical accreditation in both Canada and the USA. Designed specifically for oral cancer prediction, STRATICYTE® provides objective, personalized 5-year risk assessment to support earlier detection and better outcomes.

At Proteocyte AI, we’re committed to shaping the future of cancer prognostics—one innovation at a time.


Dental Association des chirurgiens dentistes du Québec - ACDQ Cancer Foundation Dental Association Care Manitoba Association of Oral and Maxillofacial Surgeons Cancer Society Dental Association Partnership Against Cancer Research Society québécoise du cancer Dental Association Brunswick Dental Society and Labrador Dental Association Scotia Dental Association Dental Association (ODA) Society of Oral & Maxillofacial Surgeons The Terry Fox Foundation The Princess Margaret Cancer Foundation Academy of Otolaryngology ACADEMY OF ORAL MEDICINE Academy of Oral and Maxillofacial Pathology Association of Oral and Maxillofacial Surgeons American Cancer Society American Dental Association Oral & Maxillofacial Surgeons Oral Surgery & Neck Cancer Alliance Science Foundation Oral Cancer Foundation
Oral Health Jaw Surgery of OMS Administrators
SPOHNC Mouth Cancer Foundation FoundationOral Health Foundation events

Join Proteocyte at the AAOM Winter Meeting! Proteocyte is proud to sponsor AAOM’s Winter Meeting on January 31, 2026—a l...
01/28/2026

Join Proteocyte at the AAOM Winter Meeting!

Proteocyte is proud to sponsor AAOM’s Winter Meeting on January 31, 2026—a live webinar focused on the oral–systemic connection and current best practices in oral medicine. We’re pleased to offer our community 10% off registration—use code 10PROTEOCYTE at checkout. Learn more and register: https://site.pheedloop.com/event/2026AAOMWinter/home


Dental Association des chirurgiens dentistes du Québec - ACDQ Cancer Foundation Dental Association Care Manitoba Association of Oral and Maxillofacial Surgeons Cancer Society Dental Association Partnership Against Cancer Research Society québécoise du cancer Dental Association Brunswick Dental Society and Labrador Dental Association Scotia Dental Association Dental Association (ODA) Society of Oral & Maxillofacial Surgeons Fox Foundation Princess Margaret Cancer Foundation Academy of Otolaryngology ACADEMY OF ORAL MEDICINE Academy of Oral and Maxillofacial Pathology Association of Oral and Maxillofacial Surgeons Cancer Society Dental Association Oral & Maxillofacial Surgeons Oral Surgery & Neck Cancer Alliance Science Foundation Cancer Foundation
Oral Health Jaw Surgery of OMS Administrators
Cancer Foundation Foundation Health Foundation events

Address

Toronto, ON
M5G1L7

Alerts

Be the first to know and let us send you an email when Proteocyte AI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Proteocyte AI:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram